Evidence map›Paper›PMID 37120032›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.

Fernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, Nathanael Hernandez, Anthony M Wood, Bharti Nehete, Jean Niles, Kathryn A Shelton, Sarah Kezar, Lane R Bushman and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  2. Smart closed-loop drug delivery systems.Nature reviews bioengineering · 2025
    Article
  3. Article
  4. Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Fernanda P Pons-FaudoaDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Nicola Di TraniDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Simone CapuaniDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; University of Chinese Academy of Science (UCAS), 19 Yuquan Road, Beijing 100049, China.
Nathanael HernandezDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Anthony M WoodDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Bharti NeheteDepartment of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA.
Jean NilesDepartment of Surgery, Houston Methodist Hospital, Houston, TX 77030, United States of America.
Kathryn A SheltonDepartment of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA.
Sarah KezarDepartment of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA.
Lane R BushmanDeparment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado- Anschutz Medical Campus, Aurora, CO 80045, USA.
Corrine Ying Xuan ChuaDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Michael M IttmannDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Peter L AndersonDeparment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado- Anschutz Medical Campus, Aurora, CO 80045, USA.
Pramod N NeheteDepartment of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.
Roberto C ArduinoDivision of Infectious Diseases, Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center, Houston, TX 77030, USA.
Joan E NicholsDepartment of Surgery, Houston Methodist Hospital, Houston, TX 77030, United States of America.
Alessandro GrattoniDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Surgery, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX 77030, USA. Electronic address: agrattoni@houstonmethodist.org.
Houston Methodist · USThe University of Texas MD Anderson Cancer Center · USMethodist Hospital · USBaylor College of Medicine · USThe University of Texas Health Science Center at Houston · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Montana · US

Funding

A novel nanochannel system for sustained delivery of Tenofovir Alafenamide Fumarate and Emtricitabine for HIV pre-exposure prophylaxisR01AI120749 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GRATTONI, ALESSANDRO · 2016 to 2020
$3.9M
A nanofluidic platform for tunable drug deliveryR01GM127558 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GRATTONI, ALESSANDRO, LIU, XUEWU · 2018 to 2021
$1.6M
NIAID NIH HHS R01 AI120749NIGMS NIH HHS R01 GM127558
6 · The paper itself

Abstract

Several implantable long-acting (LA) delivery systems have been developed for sustained subcutaneous administration of tenofovir alafenamide (TAF), a potent and effective nucleotide reverse transcriptase inhibitor used for HIV pre-exposure prophylaxis (PrEP). LA platforms aim to address the lack of adherence to oral regimens, which has impaired PrEP efficacy. Despite extensive investigations in this field, tissue response to sustained subcutaneous TAF delivery remains to be elucidated as contrasting preclinical results have been reported in the literature. To this end, here we studied the local foreign body response (FBR) to sustained subdermal delivery of three forms of TAF, namely TAF free base (TAF

Indexed as

Anti-HIV AgentsHIV InfectionsAdenineAlanineAnimalsMacaca mulattaRatsRats, Sprague-DawleyTenofovirAdenineAlanineAnti-HIV AgentsTenofovirForeign body responseImmune microenvironmentLong acting drug deliverySubcutaneous implantsTenofovir alafenamide

Identifiers

PMID37120032
PMCPMC10330370
OpenAlexW4367400387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.